Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL267534 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRALDH1A1USP2 | |
| SCHEMBL18548563 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRALDH1A1USP2 | |
| SCHEMBL3185849 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRALDH1A1USP2 | |
| SCHEMBL996469 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRALDH1A1USP2 | |
| SCHEMBL3181704 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRALDH1A1USP2 | |
| SCHEMBL6578082 | 0.92 | MEN1 (0.44) | MEN1KMT2ATSHRALDH1A1USP2 | |
| SCHEMBL4140372 | 0.87 | USP2 (0.63) | TSHRALDH1A1USP2KDM4ELMNA | |
| SCHEMBL4154180 | 0.87 | USP2 (0.63) | TSHRALDH1A1USP2KDM4ELMNA | |
| SCHEMBL4149480 | 0.87 | USP2 (0.63) | TSHRALDH1A1USP2KDM4ELMNA | |
| SCHEMBL4148516 | 0.87 | USP2 (0.63) | TSHRALDH1A1USP2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117715397-A | Preparation method of polyimide composite film | 深圳市睿烯新材料科技有限公司 | 2024-03-15 | — | — | CN | claimed |
| WO-2008094203-A2 | POLAR ESTER PRODRUGS OF HETEROCYCLIC HYBRID ANTIBACTERIAL COMPOUNDS AND SALTS THEREOF | MICROBIOTIX, INC. (US) | 2008-08-07 | — | — | WO | claimed |
| US-12458702-B2 | Conjugate for targeting therapy | NATIONAL TAIWAN UNIVERSITY (TW) | 2025-11-04 | — | — | US | disclosed |
| EP-4504267-A1 | CONJUGATE FOR TARGETING THERAPY | National Taiwan University (TW) | 2025-02-12 | — | — | EP | disclosed |
| CN-117715397-A | Preparation method of polyimide composite film | 深圳市睿烯新材料科技有限公司 | 2024-03-15 | — | — | CN | disclosed |
| WO-2023195839-A1 | CONJUGATE FOR TARGETING THERAPY | NATIONAL TAIWAN UNIVERSITY (TW) | 2023-10-12 | — | — | WO | disclosed |
| US-20230310618-A1 | CONJUGATE FOR TARGETING THERAPY | NATIONAL TAIWAN UNIVERSITY (TW) | 2023-10-05 | — | — | US | disclosed |
| CN-109963838-B | Dimeric contrast agents | 伯拉考成像股份公司 | 2023-04-11 | — | — | CN | disclosed |
| CN-114401731-A | Compositions and methods for treating human immunodeficiency virus | 奇达拉治疗公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-106604891-B | Non-aqueous liquid and semi-solid formulations of amorphous calcium carbonate | 艾玛菲克有限公司 | 2020-07-28 | — | — | CN | disclosed |
| EP-2842940-B1 | SULFORAPHANE-DERIVED COMPOUNDS, PRODUCTION METHOD THEREOF AND THE MEDICAL, FOOD AND COSMETIC USE OF SAME | CONSEJO SUPERIOR INVESTIGACION (ES) | 2018-04-25 | — | — | EP | disclosed |
| EP-2846784-A1 | COMPOUNDS USEFUL FOR PROMOTING PROTEIN DEGRADATION AND METHODS USING SAME | Yale University (US) | 2015-03-18 | — | — | EP | disclosed |
| EP-2842940-A1 | SULFORAPHANE-DERIVED COMPOUNDS, PRODUCTION METHOD THEREOF AND THE MEDICAL, FOOD AND COSMETIC USE OF SAME | Consejo Superior De Investigaciones Científicas (CSIC) (ES) | 2015-03-04 | — | — | EP | disclosed |
| US-20150037419-A1 | Functional PLA-PEG Copolymers, the Nanoparticles Thereof, Their Preparation and Use for Targeted Drug Delivery and Imaging | SANOFI (FR) | 2015-02-05 | — | — | US | disclosed |
| US-8623606-B2 | Screening method for GPCR ligands | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2014-01-07 | — | — | US | disclosed |
| WO-2013170147-A1 | COMPOUNDS USEFUL FOR PROMOTING PROTEIN DEGRADATION AND METHODS USING SAME | YALE UNIVERSITY (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20120149843-A1 | NANOFIBERS AND MORPHOLOGY SHIFTING MICELLES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011017382-A2 | NANOFIBERS AND MORPHOLOGY SHIFTING MICELLES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-02-10 | — | — | WO | disclosed |
| US-20090286259-A1 | SCREENING METHOD FOR GPCR LIGANDS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2009-11-19 | — | — | US | disclosed |
| WO-2008094203-A2 | POLAR ESTER PRODRUGS OF HETEROCYCLIC HYBRID ANTIBACTERIAL COMPOUNDS AND SALTS THEREOF | MICROBIOTIX, INC. (US) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149843-A1 | NANOFIBERS AND MORPHOLOGY SHIFTING MICELLES | MFAP1, LGALS4, TLN1 | MEN1 412/4885KMT2A 2800/4885TSHR 4613/4885 |
| US-20090286259-A1 | SCREENING METHOD FOR GPCR LIGANDS | GPR139, GRK2, GPR27 | MEN1 4098/4885KMT2A 3694/4885TSHR 371/4885 |
| US-12458702-B2 | Conjugate for targeting therapy | FOLH1, CD44, SLC10A1 | MEN1 439/4885KMT2A 608/4885TSHR 1876/4885 |
| US-20150037419-A1 | Functional PLA-PEG Copolymers, the Nanoparticles Thereof, Their Preparation and Use for Targeted Drug Delivery and Imaging | NAPEPLD, LPXN, PCNP | MEN1 3378/4885KMT2A 4295/4885TSHR 4575/4885 |
| US-20230310618-A1 | CONJUGATE FOR TARGETING THERAPY | FOLH1, CD44, SLC10A1 | MEN1 439/4885KMT2A 608/4885TSHR 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.